Stock Ratings from Analyst Ratings Network

Open Main Menu Open Sidebar

Stemline Therapeutics Company Profile (NASDAQ:STML)

Consensus Ratings for Stemline Therapeutics (NASDAQ:STML) (?)
Ratings Breakdown: 1 Sell Rating(s), 4 Buy Rating(s)
Consensus Rating:Buy (Score: 2.60)
Consensus Price Target: $44.20 (234.60% upside)

Analysts' Ratings History for Stemline Therapeutics (NASDAQ:STML)
Show:
DateFirmActionRatingPrice TargetDetailsShare
10/14/2014ZacksUpgradeNeutral -> Outperform$12.60ViewTweet This Rating  Share This Rating on StockTwits
5/19/2014Jefferies GroupLower Price TargetBuy$60.00 -> $50.00ViewTweet This Rating  Share This Rating on StockTwits
5/16/2014Roth CapitalReiterated RatingBuyViewTweet This Rating  Share This Rating on StockTwits
2/12/2014WBB SecuritiesInitiated CoverageSellViewTweet This Rating  Share This Rating on StockTwits
11/14/2013Roth CapitalBoost Price TargetBuy$50.00 -> $55.00ViewTweet This Rating  Share This Rating on StockTwits
11/13/2013AegisReiterated RatingBuy$70.00ViewTweet This Rating  Share This Rating on StockTwits
10/30/2013AegisBoost Price TargetBuy$40.00 -> $70.00ViewTweet This Rating  Share This Rating on StockTwits
9/11/2013WedbushInitiated CoverageOutperform$49.00ViewTweet This Rating  Share This Rating on StockTwits
8/29/2013Jefferies GroupInitiated CoverageBuy$60.00ViewTweet This Rating  Share This Rating on StockTwits
8/19/2013Ladenburg ThalmannBoost Price TargetBuy$36.00 -> $44.00ViewTweet This Rating  Share This Rating on StockTwits
7/30/2013Roth CapitalInitiated CoverageBuy$50.00ViewTweet This Rating  Share This Rating on StockTwits
6/21/2013AegisBoost Price TargetBuy$35.00 -> $40.00ViewTweet This Rating  Share This Rating on StockTwits
6/18/2013Ladenburg ThalmannReiterated RatingBuy$36.00ViewTweet This Rating  Share This Rating on StockTwits
5/4/2013Ativo ResearchInitiated CoverageNeutralViewTweet This Rating  Share This Rating on StockTwits
3/18/2013AegisInitiated CoverageBuy$35.00ViewTweet This Rating  Share This Rating on StockTwits
2/12/2013WBB SecuritiesInitiated CoverageSell$9.00ViewTweet This Rating  Share This Rating on StockTwits
(Data available from 10/21/2012 forward)
Discuss Stemline Therapeutics